Gelesis Holdings, Inc. (GLS)
NYSE NYSE Primary Summary
Royal Mail's sister business GLS to buy 20% stake in Greece's ACS for $80 million
Parcel services firm GLS, the international sister business to the UK's Royal Mail, has agreed to buy a 20% stake in Greece's ACS for 74 million euros ($80.06 million), their parent International Distribution Services said on Monday.
Royal Mail, GLS need sizable investments soon, billionaire suitor Kretinsky says
Royal Mail and its international parcels network GLS need sizable, almost immediate investments to defend market share and face shifting market trends, Czech billionaire Daniel Kretinsky told Reuters on Wednesday after the group's owner agreed to a 3.57 billion pound ($4.55 billion) takeover.
Gelesis Holdings, Inc. (GLS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Gelesis Holdings, Inc. ever had a stock split?
Gelesis Holdings, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Alessandro Sannino CEO | NYSE Exchange | 36850R204 CUSIP |
| US Country | 93 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Gelesis Holdings, Inc. was a commercial-stage biotherapeutics company focused on developing innovative solutions to combat obesity and gastrointestinal (GI)-related chronic diseases through biomimicry. Established in 2006 and based in Boston, Massachusetts, the company aimed to address some of the most pressing health issues of modern times with its unique approach towards weight management and GI health. Notably, on October 30, 2023, Gelesis Holdings, Inc., along with its affiliates, entered into a voluntary liquidation process under Chapter 7 of the U.S. Bankruptcy Court for the District of Delaware, marking the end of its operational journey.
Products and Services
- PLENITY
An innovative, non-systemic, and non-stimulant weight management aid designed for oral administration. PLENITY works by aiding in weight control, targeting adults with a Body Mass Index (BMI) in the overweight to obese range. It is an example of the company's dedication to providing solutions for weight management without the need for systemic drugs or stimulants, aligning with their biomimicry approach.
- GS200
In development for weight loss in individuals with prediabetes and type 2 diabetes, GS200 represents Gelesis Holdings, Inc.'s commitment to addressing the specific needs of patients dealing with metabolic disorders. This product aims to provide a targeted approach to weight management in a population at high risk for obesity-related complications.
- GS500
Targeted at improving outcomes for patients suffering from functional constipation, GS500 is another innovative product in the company's pipeline. It exemplifies Gelesis Holdings, Inc.'s efforts to expand their solutions beyond weight management and into the broader realm of gastrointestinal health, offering potential relief for a common GI issue.
- GS300
A pre-clinical product being developed for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). GS300 underscores the company's expansion into treating more severe GI-related chronic diseases through their biomimetic approach, targeting conditions with significant unmet medical needs.
